Pill Identifier App

Generic Trisenox Availability

Trisenox is a brand name of arsenic trioxide, approved by the FDA in the following formulation(s):

TRISENOX (arsenic trioxide - injectable;injection)

  • Manufacturer: CEPHALON
    Approval date: September 25, 2000
    Strength(s): 1MG/ML [RLD]

Has a generic version of Trisenox been approved?

No. There is currently no therapeutically equivalent version of Trisenox available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trisenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,723,351
    Issued: April 20, 2004
    Inventor(s): Raymond P.; Warrell, Jr. & Pier Paolo; Pandolfi & Janice L.; Gabrilove
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:
    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,855,339
    Issued: February 15, 2005
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:
    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,861,076
    Issued: March 1, 2005
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:
    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,884,439
    Issued: April 26, 2005
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:
    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 6,982,096
    Issued: January 3, 2006
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:
    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
  • Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
    Patent 8,273,379
    Issued: September 25, 2012
    Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
    Assignee(s): Memorial Sloan-Kettering Cancer Center
    The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
    Patent expiration dates:
    • November 10, 2018
      ✓ 
      Patent use: TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)